{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:23:11Z","timestamp":1789593791977,"version":"build-2803163510"},"reference-count":86,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Cancer vaccines have resurged in oncology because they address a central question in precision medicine: whether the molecular identity of a tumor can be converted into an immune target that is both specific and clinically useful. Preventive vaccines against oncogenic viruses have already shown that immune intervention can reduce the burden of virus-associated cancers. Therapeutic cancer vaccines face a more difficult task, because established tumors arise from self-tissues, change over time, and often acquire mechanisms that limit antigen presentation, T-cell entry, or immune-mediated killing. This review examines cancer vaccines as biomarker-driven tools within precision oncology. The focus is not only on vaccine platforms, but on the biological requirements that make an antigen suitable for therapeutic targeting. Tumor-specific mutations, viral antigens, recurrent driver alterations, frameshift peptides, cancer-testis antigens, and personalized neoantigens may all provide vaccine targets, but their presence alone is not enough. A clinically relevant vaccine antigen should be expressed by tumor cells, processed and presented through HLA molecules, recognized by functional T cells, and sufficiently retained during tumor evolution. This distinction is particularly important because sequencing and computational prediction now generate many candidate neoantigens whose immunological relevance still requires experimental confirmation. Particular attention is given to antigen-presentation defects, clonal and subclonal heterogeneity, tumor microenvironment barriers, circulating tumor DNA-defined minimal residual disease, and immune-response monitoring. Colorectal cancer is used as a working model because microsatellite instability-high\/mismatch repair-deficient tumors, microsatellite-stable tumors with immune-resistant features, and recurrent alterations in MMR genes, KRAS, BRAF, adenomatous polyposis coli, and TP53 illustrate how cancer-cell signaling, neoantigen generation, tumor microenvironment remodeling, and patient stratification intersect. Overall, cancer vaccines are unlikely to become universal stand-alone treatments for advanced solid tumors. Their most credible role may emerge in molecularly selected patients, adjuvant therapy, minimal residual disease, virus-associated malignancies, and rational combinations with checkpoint inhibitors or tumor microenvironment-modulating agents.<\/jats:p>","DOI":"10.3389\/fcell.2026.1897032","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T07:14:40Z","timestamp":1787296480000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Mechanistic biomarkers for cancer vaccine development: from cancer cell biology to neoantigen-guided precision immunotherapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Dario","family":"Rusciano","sequence":"first","affiliation":[{"name":"Independent Researcher","place":["Livorno, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov."},{"key":"B3","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.cell.2018.09.018","article-title":"Evolution of metastases in space and time under immune selection","volume":"175","author":"Angelova","year":"2018","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.3390\/cancers12092607","article-title":"The origin and immune recognition of tumor-specific antigens","volume":"12","author":"Apavaloaei","year":"2020","journal-title":"Cancers"},{"key":"B5","doi-asserted-by":"publisher","first-page":"CD009069","DOI":"10.1002\/14651858.CD009069.pub3","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1074\/mcp.M114.042812","article-title":"Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation","volume":"14","author":"Bassani-Sternberg","year":"2015","journal-title":"Mol. & Cell. Proteomics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"902899","DOI":"10.3389\/fimmu.2022.902899","article-title":"Target validation by immunopeptidomics for epitope-specific immunotherapies","volume":"13","author":"Becker","year":"2022","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3390\/cancers13040845","article-title":"Novel protein-based vaccine against self-antigen reduces the formation of sporadic Colon adenomas in mice","volume":"13","author":"Belnoue","year":"2021","journal-title":"Cancers"},{"key":"B10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/vaccines8040615","article-title":"Selecting target antigens for cancer vaccine development","volume":"8","author":"Buonaguro","year":"2020","journal-title":"Vaccines."},{"key":"B12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1054231","DOI":"10.3389\/fonc.2022.1054231","article-title":"Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy","volume":"12","author":"Cai","year":"2023","journal-title":"Front. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"eadv6445","DOI":"10.1126\/sciadv.adv6445","article-title":"Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy","volume":"11","author":"Cai","year":"2025","journal-title":"Sci. Adv."},{"key":"B15","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/jnci\/djp288","article-title":"Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study","volume":"101","author":"Chang","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"B17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12935-020-1117-2","article-title":"The heterogeneous clinical and pathological landscapes of metastatic BRAF-Mutated colorectal cancer","volume":"20","author":"Fanelli","year":"2020","journal-title":"Cancer Cell Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1053\/j.gastro.2021.06.073","article-title":"Recurrent frameshift neoantigen vaccine elicits protective immunity with reduced tumor burden and improved overall survival in a Lynch syndrome mouse model","volume":"161","author":"Gebert","year":"2021","journal-title":"Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1158\/0008-5472.CAN-20-4026","article-title":"Patient-derived organoids for precision cancer immunotherapy","volume":"81","author":"Gr\u00f6nholm","year":"2021","journal-title":"Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/21598290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"B31","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"eabc8697","DOI":"10.1126\/science.abc8697","article-title":"Targeting a neoantigen derived from a common TP53 mutation","volume":"371","author":"Hsiue","year":"2021","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/2326-6066.CIR-19-0401","article-title":"pVACtools: a computational toolkit to identify and visualize cancer neoantigens","volume":"8","author":"Hundal","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non-small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1158\/1078-0432.CCR-19-3517","article-title":"A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers: a phase I\/IIa clinical trial","volume":"26","author":"Kloor","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"eaau5516","DOI":"10.1126\/scitranslmed.aau5516","article-title":"Noncoding regions are the main source of targetable tumor-specific antigens","volume":"10","author":"Laumont","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","first-page":"xii11","DOI":"10.1093\/annonc\/mdx681","article-title":"Preclinical and clinical development of neoantigen vaccines","volume":"28","author":"Li","year":"2017","journal-title":"Ann. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat. Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10585-023-10246-2","article-title":"Dissecting the tumor microenvironment in response to immune checkpoint inhibitors via single-cell and spatial transcriptomics","volume":"41","author":"Liu","year":"2024","journal-title":"Clin. & Exp. Metastasis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov."},{"key":"B45","doi-asserted-by":"publisher","first-page":"6566","DOI":"10.1038\/s41467-023-42010-1","article-title":"KRAS G12V neoantigen-specific T cell receptor for adoptive T cell therapy of pancreatic cancer","volume":"14","author":"Lu","year":"2023","journal-title":"Nat. Commun."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/beta-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","volume":"551","author":"Luksza","year":"2017","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","first-page":"726239","DOI":"10.1155\/2013\/726239","article-title":"Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays","volume":"2013","author":"Macchia","year":"2013","journal-title":"BioMed Res. Int."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.trecan.2021.07.006","article-title":"HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy","volume":"7","author":"Maggs","year":"2021","journal-title":"Trends Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI123791","article-title":"Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers","volume":"129","author":"Malekzadeh","year":"2019","journal-title":"J. Clin. Investigation"},{"key":"B51","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF beta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cels.2020.06.010","article-title":"MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing","volume":"11","author":"O'Donnell","year":"2020","journal-title":"Cell Syst."},{"key":"B55","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"key":"B61","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"B63","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B65","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B66","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF beta drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","first-page":"8947","DOI":"10.1073\/pnas.0703395104","article-title":"Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody\/Th1 responses and CD8 T cells through cross-priming","volume":"104","author":"Valmori","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.3389\/fimmu.2017.01887","article-title":"Adenosine, lactate, acidosis, vascular endothelial growth factor, potassium ions and phosphatidylserine: key contributors to the immune escape of cancer cells","volume":"8","author":"Vaupel","year":"2017","journal-title":"Front. Immunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1172\/JCI98689","article-title":"Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma","volume":"128","author":"Veatch","year":"2018","journal-title":"J. Clin. Investigation"},{"key":"B74","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature18945","article-title":"Neoantigen landscape dynamics during human melanoma-T cell interactions","volume":"536","author":"Verdegaal","year":"2016","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1424351","DOI":"10.3389\/fimmu.2024.1424351","article-title":"TP53 mutation-mediated immune evasion in cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma: a randomised, open-label, phase 2b trial","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"B77","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1078-0432.CCR-18-0856","article-title":"Immune activation in mismatch repair-deficient carcinogenesis: more than just mutational rate","volume":"26","author":"Willis","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13073-024-01384-7","article-title":"pVACview: an interactive visualization tool for efficient neoantigen prioritization and selection","volume":"16","author":"Xia","year":"2024","journal-title":"Genome Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41591-019-0434-2","article-title":"Immunogenic neoantigens derived from gene fusions stimulate T cell responses","volume":"25","author":"Yang","year":"2019","journal-title":"Nat. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"B81","first-page":"4568","article-title":"Humanized mouse model: a review on preclinical applications for cancer immunotherapy","volume":"10","author":"Yin","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.3390\/ijms26104559","article-title":"Signature gene mutations in colorectal cancer: potential neoantigens for cancer vaccines","volume":"26","author":"Yoon","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B83","doi-asserted-by":"publisher","first-page":"5999","DOI":"10.1073\/pnas.1602069113","article-title":"NLRC5\/MHC class I transactivator is a target for immune evasion in cancer","volume":"113","author":"Yoshihama","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B84","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"bbad436","DOI":"10.1093\/bib\/bbad436","article-title":"Accurate TCR-pMHC interaction prediction using a BERT-based transfer learning method","volume":"25","author":"Zhang","year":"2023","journal-title":"Briefings Bioinforma."},{"key":"B86","doi-asserted-by":"publisher","first-page":"bbaa126","DOI":"10.1093\/bib\/bbaa126","article-title":"TSNAD v2.0: a one-stop software solution for tumor-specific neoantigen detection","volume":"22","author":"Zhou","year":"2021","journal-title":"Briefings Bioinforma."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1897032\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T07:14:41Z","timestamp":1787296481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1897032\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":86,"alternative-id":["10.3389\/fcell.2026.1897032"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1897032","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1897032"}}